Panavir, gel 0.002% 3 g

Panavir® is a purified extract of the shoots of the plant Solanum tuberosum; the main active ingredient is a hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, uronic acids.

Panavir® is an antiviral and immunomodulatory agent. It increases nonspecific resistance to various infections and promotes induction of interferon alpha and gamma by blood leukocytes.

The drug is well tolerated in therapeutic doses.

Tests showed absence of mutagenic, teratogenic, carcinogenic, allergic and embryotoxic action. In preclinical studies on laboratory animals no negative effects on reproductive function and fetal development were found.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the test of pseudoallergic inflammatory reaction to concanavalin A.

The analgesic effect in models of neurogenic pain and pain caused by inflammation and thermal irritation is shown.

It has antipyretic effect.

In a model of parkinsonian syndrome caused by systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neuroprotective properties have been shown.

It has the ability to improve retinal and optic nerve function.

It has wound-healing properties in a gastric ulcer model.

Indications

Infectious inflammatory diseases of the skin and/or mucous membranes caused by herpes simplex virus Herpes simplex types I and II, including genital herpes.

Active ingredient

Composition

Active ingredient:

Panavir® (polysaccharides of the shoots of Solanum tuberosum)0.002 g;

Auxiliary substances:

Glycerol – 30 g;

Macrogol 4000 – 15 g;

Macrogol 400 – 38 g;

Ethanol 95% – 1 g;

sodium hydroxide – 0.4 g;

lanthanum nitrate hexahydrate – 2.2 g;

water – up to 100 g;

How to take, the dosage

Externally and topically.

The gel is applied thinly to the affected areas of the skin and/or mucous membranes 5 times a day.

The duration of treatment is 4-5 days.

The course of treatment may be extended up to 10 days.

Special Instructions

It is recommended to start treatment as early as possible, at the first signs of the disease (itching, tingling, redness, feeling of tension), so that the development of the blister stage of the disease can be completely prevented.

Panavir® Gel is not intended for use in ophthalmology.

When applying the gel to the face, avoid getting it in the eyes.

Contraindications

Side effects

Possible occurrence of rapid redness and itching of the skin and/or mucous membranes in the area where the gel is applied.

Pregnancy use

Pregnant use is possible only when the estimated benefit to the mother exceeds the potential risk to the fetus.

If it is necessary to use the drug during lactation, breastfeeding should be stopped for the period of the drug use.